TABLE 1.
Summary and Comparison a of Biomarkers among Lobular Carcinoma In Situ (LCIS) Subtypes
| ER b | PR b | AR b | mean Ki-67 | HER2 e | GCDFP-15 e | CK5/6 e | |
|---|---|---|---|---|---|---|---|
| CLCIS (N=21) | 248 (100%) |
228 (100%) |
246 (100%) |
4.2% | 0% | Not done | 19% |
| All PLCIS (N=31) |
109 c (66%) |
94 c (62%) |
199 (100%) |
11.5% c | 13% | 74% | 23% |
| Non apocrine PLCIS (N=18) |
160c (100%) |
129c (94%) |
168 c (100%) |
9.9% c | 0% | 50% | 28% |
| Apocrine PLCIS (N=13) |
47 c,d (23%) |
45 c,d (17%) |
246 d (100%) |
13.9% c | 31% c,d | 100% d | 17% |
CLCIS, classic LCIS; PLCIS, pleomorphic PLCIS.
a
Wilcoxon Mann Whitney test (t-test) for ER, PR, AR and Ki-67; Fisher’s exact test (chi-square test) for HER2, GCDFP-15 and CK5/6
b
Expressed as mean H score (% of cases positive)
c
p <0.05 for comparison with CLCIS
d
p <0.05 apocrine vs non-apocrine PLCIS
e
% of cases positive